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Background
Cancer is a multi-genic, complex biological phenomenon
and its growth is affected by various categories of factors
including the genetics of the host, the accumulating
genetic alteration within cancer cells and environmental
modifiers.
Material and methods
Therefore, to identify the determinants of immune-
mediated tumor rejection during immunotherapy, a sys-
tematic and comprehensive monitoring approach needs
to be applied that covers the various categories at a time
relevant to the therapeutic intervention. In addition, a
temporal dimension needs to be added to evaluate in
real time the changes induced by treatment and their
relationship with clinical outcome.
Results
In this presentation, we will review the salient concepts
that should guide the future monitoring of clinical trials
taking advantage of novel and comprehensive technologi-
cal advances presenting examples of integrated approaches
for the assessment of patients’ response to adoptive T cell
therapy.
Conclusions
Our experience highlights the need to apply multi-
parametric approaches for the understanding of the
mechanism(s) leading to cancer rejection by the immune
system in humans.
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